Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISHL12 2022 | Improving tools and techniques for MRD detection in Hodgkin lymphoma

Sven Borchmann • 20 Oct 2022
ISHL12 2022
Hodgkin Lymphoma Leukemia Lymphoma

Sven Borchmann, MD, University of Cologne, Cologne, Germany, discusses the importance of measurable residual disease (MRD) in Hodgkin lymphoma (HL), highlighting the value of finding sensitive biomarkers for MRD such as circulating tumor DNA. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Ownership interest in and am founder of Liqomics

More from Sven Borchmann

1:17
The importance of risk-adapted therapies in Hodgkin lymphoma
Sven Borchmann • 15 Jun 2023
1:27
Challenges in understanding the genomic landscape of Hodgkin lymphoma
Sven Borchmann • 15 Jun 2023
0:53
The current state of MRD in Hodgkin lymphoma
Sven Borchmann • 15 Jun 2023
1:47
Using peripheral blood ctDNA-sequencing for PCNSL risk profiling
Sven Borchmann • 10 Dec 2022

Related Videos

1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals